What is the recommended management of diabetic ketoacidosis?

Management of Diabetic Ketoacidosis

For moderate-to-severe DKA, initiate continuous intravenous insulin infusion at 0.1 units/kg/hour (without a bolus) alongside aggressive fluid resuscitation with isotonic crystalloids, targeting a glucose decline of 50-75 mg/dL per hour until resolution criteria are met (glucose <200 mg/dL, bicarbonate ≥18 mEq/L, venous pH >7.3). 1

Initial Assessment and Diagnosis

DKA is confirmed by the triad of:

• Metabolic acidosis: pH <7.3, bicarbonate <18 mEq/L, anion gap >10 mEq/L
• Ketosis: Elevated serum or urine ketones (β-hydroxybutyrate preferred)
• Hyperglycemia: Traditionally >250 mg/dL, though euglycemic DKA is increasingly recognized 2, 3

Critical pitfall: Do not rely on urine ketone testing by nitroprusside method during treatment monitoring—it only measures acetoacetate and acetone, not β-hydroxybutyrate (the predominant ketoacid). As β-hydroxybutyrate converts to acetoacetate during therapy, nitroprusside testing may falsely suggest worsening ketosis 1.

Obtain immediately: electrolytes, venous blood gas (arterial unnecessary for monitoring), glucose, BUN, creatinine, phosphate, urinalysis, CBC with differential, A1C, and ECG 2.

Fluid Resuscitation

Start with 1-1.5 L of isotonic crystalloid (0.9% saline or lactated Ringer's) over the first hour 1. Recent evidence suggests lactated Ringer's may achieve faster resolution of high anion gap metabolic acidosis compared to normal saline without increasing complications 4.

After initial resuscitation:

• Continue isotonic fluids at 250-500 mL/hour, adjusting based on hydration status and serum sodium
• Critical consideration: Use isotonic or hypotonic saline judiciously depending on corrected serum sodium and hemodynamic status to avoid cerebral edema, particularly in pediatric patients 1

Insulin Therapy

Moderate-to-Severe DKA

Continuous IV insulin infusion is preferred (Grade B recommendation) 1:

• Start at 0.1 units/kg/hour without an initial bolus
• Target glucose decline of 50-75 mg/dL per hour
• If glucose fails to decline adequately, double the infusion rate hourly until target decline achieved 1
• When glucose reaches 200 mg/dL, add 5% dextrose to IV fluids and continue insulin infusion
• Do not stop insulin until ketoacidosis resolves, even if glucose normalizes

Mild DKA

Subcutaneous or intramuscular regular insulin is equally effective 1:

• Give priming dose of 0.4-0.6 units/kg (half IV bolus, half SC/IM)
• Continue 0.1 unit/kg SC or IM every hour

Major pitfall: Never abruptly discontinue IV insulin when transitioning to subcutaneous regimen. Continue IV insulin for 1-2 hours after starting subcutaneous insulin to maintain adequate plasma insulin levels and prevent rebound hyperglycemia 1, 5.

Electrolyte Management

Potassium

• Hold insulin if potassium <3.3 mEq/L and aggressively replace potassium first
• If potassium 3.3-5.3 mEq/L: add 20-30 mEq potassium to each liter of IV fluid
• If potassium >5.3 mEq/L: monitor closely but do not add potassium initially
• Use 2/3 potassium chloride and 1/3 potassium phosphate 1

Phosphate

Routine phosphate replacement has not shown benefit on clinical outcomes (Grade A evidence) 1. However, consider careful replacement if:

• Serum phosphate <1.0 mg/dL
• Cardiac dysfunction present
• Anemia present
• Respiratory depression present

Bicarbonate

Bicarbonate therapy is not necessary if pH ≥7.0 (Grade C recommendation) 1:

• Consider 1-2 mEq/kg sodium bicarbonate over 1 hour if pH <6.9 after initial hydration
• In pediatric patients with pH <7.0 after initial hydration, administer bicarbonate cautiously

Monitoring

Draw labs every 2-4 hours for:

• Electrolytes, glucose, BUN, creatinine, osmolality
• Venous pH (arterial blood gases generally unnecessary) 1
• Anion gap calculation to monitor acidosis resolution

Monitor β-hydroxybutyrate directly if available—this is the preferred method for tracking ketone clearance 1.

Resolution Criteria

DKA is resolved when all three criteria are met 1:

1. Glucose <200 mg/dL
2. Serum bicarbonate ≥18 mEq/L
3. Venous pH >7.3

Transition to Subcutaneous Insulin

Once DKA resolves:

• If patient NPO: continue IV insulin and supplement with subcutaneous regular insulin every 4 hours as needed
• If patient able to eat: initiate basal-bolus regimen (combination of rapid/short-acting and intermediate/long-acting insulin)
• Continue IV insulin for 1-2 hours after first subcutaneous dose to ensure adequate overlap 1

Special Considerations

SGLT2 Inhibitor-Associated DKA

The use of SGLT2 inhibitors modestly increases DKA risk, including euglycemic DKA 2. Discontinue SGLT2 inhibitors immediately and maintain high index of suspicion for DKA even with normal glucose levels 6, 7.

High-Risk Patients

Tailor management for:

• Pregnancy: Requires more aggressive monitoring
• Renal disease/heart failure: Adjust fluid rates carefully to avoid volume overload
• Elderly patients: Consider lower insulin starting doses (0.05-0.075 units/kg/hour)
• Post-surgical patients: Maintain heightened awareness for euglycemic DKA 6, 7

Cerebral Edema Prevention

Particularly critical in pediatric patients:

• Avoid excessive fluid administration (do not exceed 2× maintenance requirements in children) 1
• Correct glucose and osmolality gradually
• Monitor neurological status closely

Common Pitfalls to Avoid

1. Premature discontinuation of IV insulin before ketoacidosis resolves (most common error) 5
2. Insufficient overlap when transitioning from IV to subcutaneous insulin 1, 5
3. Using nitroprusside ketone testing to monitor treatment response 1
4. Stopping insulin when glucose normalizes while acidosis persists—add dextrose instead 1
5. Failing to identify and treat precipitating cause (infection, medication nonadherence, new diagnosis) 2, 8